Terminally ill broadcaster Esther Rantzen sparks controversy with comments on Assisted Dying Bill
Steelers explore acquiring Saints' Chris Olave to bolster receiving corps, but a trade is not imminent.
Novo Nordisk CEO steps down amid market challenges, including competition from Eli Lilly's rival drug and setbacks with Novo Nordisk's obesity treatments.
Terminally ill broadcaster Esther Rantzen sparks controversy with comments on Assisted Dying Bill
Steelers explore acquiring Saints' Chris Olave to bolster receiving corps, but a trade is not imminent.
Novo Nordisk CEO steps down amid market challenges, including competition from Eli Lilly's rival drug and setbacks with Novo Nordisk's obesity treatments.